Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy

Neurology

Volumn 64, Issue 3, 2005, Pages 475-480

  Beydoun, A ^a   Uthman, B M ^c   Kugler, A R ^b   Greiner, M J ^b   Knapp, L E ^b   Garofalo, E A ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; PLACEBO; PREGABALIN; TOPIRAMATE;

ADULT; AGED; AMBLYOPIA; ARTICLE; ASTHENIA; ATAXIA; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; HUMAN; LABORATORY TEST; MALE; MULTICENTER STUDY; NEUROLOGIC EXAMINATION; OBSTRUCTIVE JAUNDICE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; THOUGHT DISORDER; WEIGHT GAIN;

EID: 13244277459     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000150932.48688.BE     Document Type: Article

References (17)

1. Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999;19:149-177.
2. Gee NS, Brown JP, Dissanayake UV, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271: 5768-5776.
3. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-110.
4. 3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-1093.
5. 3H] glutamate from rat caudal trigeminal nucleus slices. Pain 2001;93:191-196.
6. 2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-236.
7. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference. Epilepsy Res 2002;51:31-71.
8. Feng MR, Turluck D, Burleigh J, et al. Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet 2001;26:123-128.
9. French JA, Kugler AR, Robbins JL, et al. Dose - response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60:1274-1283.
10. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45:20-27.
11. Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995;36:1111-1117.
12. Montouris GD. Practical insights and clinical experience with combinations of the new antiepileptic drugs. Neurology 1995;45:S25-S28.
13. Garnett WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy 2000;20:191-199.
14. Richter A, Anton SF, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-2335.
15. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group. Arch Neurol 1997;54:595-601.
16. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
17. Deckers CL, Hekster YA, Keyser A, Meinardi H, Renier WO. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia 1997;38:570-575.